局部晚期宫颈癌接受放化疗与近距离治疗患者中的血栓预防
这项前瞻性观察研究纳入89例在两个荷兰三级医院接受根治性放化疗的原发性局部晚期宫颈癌患者,治疗期间给予高剂量血栓预防。临床和亚临床静脉血栓栓塞事件累积发生率为7.9%(n=7),其中亚临床静脉血栓栓塞3例(3.4%)、临床静脉血栓栓塞4例(4.5%),近距离治疗后出血不良事件8例。
要点
- 局部晚期宫颈癌放化疗及近距离治疗期间给予高剂量血栓预防,血栓栓塞事件累积发生率为7.9%(n=7)。
- 亚临床静脉血栓栓塞3例(3.4%),临床静脉血栓栓塞4例(4.5%),近距离治疗后出血不良事件8例。
- 作者认为需进一步研究识别高危因素,以对高危患者进行针对性筛查和预防。
核心结论
- 局部晚期宫颈癌患者常规血栓预防使放化疗和近距离治疗期间血栓栓塞事件发生率相对较低。
- 进一步研究应聚焦于识别导致高危患者针对性筛查和预防静脉血栓栓塞的高危因素。
研究设计与样本
- 前瞻性观察研究,2021年8月至2023年12月在两个荷兰三级医院纳入89例接受根治性放化疗的原发性局部晚期宫颈癌患者。
- 患者在放化疗和近距离治疗期间接受高剂量血栓预防。
- 在总治疗时间的第4或第5周测定血浆D-二聚体水平,所有患者接受下肢静脉超声筛查深静脉血栓形成(DVT)。
- 如有指征,患者接受CT血管造影筛查肺栓塞(PE)。
主要发现
- 89例患者中临床和亚临床(静脉)血栓栓塞事件累积发生率为7.9%(n=7)。
- 深静脉血栓形成2例,肺栓塞3例,深静脉血栓形成合并肺栓塞1例,动脉血栓栓塞事件(ATE)1例。
- 3例(3.4%)为亚临床静脉血栓栓塞,在近距离治疗前筛查中诊断;4例(4.5%)为临床静脉血栓栓塞,其中2例在放化疗期间发生、1例在因近距离治疗住院期间发生、1例在完成治疗后发生。
- 7例静脉血栓栓塞患者中2例(28.6%)接受热疗。
- 近距离治疗后出血不良事件发生于8例患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the incidence of clinical and subclinical venous thromboembolic events (VTE) in patients with locally advanced cervical cancer (LACC) treated with high-dose thromboprophylaxis during definitive chemoradiation and brachytherapy. METHODS: A prospective observational study was undertaken from August 2021 to December 2023 in patients with primary LACC treated with definitive chemoradiation in two Dutch tertiary hospitals. Patients received high-dose thromboprophylaxis during chemoradiation and brachytherapy. In week 4 or 5 of the overall treatment time, plasma D-dimer levels were determined, and all patients underwent venous ultrasound imaging of the legs to screen for deep vein thrombosis (DVT). If indicated, patients received a CT-angiography to screen for pulmonary embolism (PE). RESULTS: Among 89 included patients, cumulative incidence of clinical and subclinical (V)TE was 7.9 % (n = 7). DVT was found in two patients, PE in three patients, DVT and PE in one patient and one patient had an arterial thromboembolic event (ATE). Of these patients, three (3.4 %) had subclinical VTE, diagnosed during the screening before brachytherapy, and four (4.5 %) had clinical VTE of whom two developed VTE during chemoradiation, one during hospitalization for brachytherapy and one after completing treatment. Of the seven patients with VTE, two (28.6 %) were treated with hyperthermia. Adverse bleeding events after brachytherapy occurred in eight patients. CONCLUSION: Routine thromboprophylaxis in patients with LACC leads to a relative low incidence of thromboembolic events during chemoradiation and brachytherapy. Further research should focus on identifying high risk factors leading to targeted screening and prevention of VTE in high risk patients.
引用
- Leijtens L, Piek J, Verrijssen AS, et al. Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy. Gynecol Oncol. 2025. PMID: 39778332. doi:10.1016/j.ygyno.2024.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。